SIETES :: 93212 citas

Resultados de la búsqueda por USA REFINAR BÚSQUEDA

1.

Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med 2021;384:18 de febrero. [Ref.ID 103836]

2.

VRBPAC Briefing Document. Pfizer-BioNTech Covid-19 vaccine (bnt162, pf-07302048) Vaccines and Related Biological Products Advisory Committee. Briefing document. Meeting date: 10 December 2020. U.S. Food and Drug Administration 2020:14 de diciembre. [Ref.ID 103835]

3.

Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, McClung N, Campos-Oucalt D, Morgan RL, Mbaeyi S, Romero JR, Talbot HK, Lee GM, Bell BP, Dooling K. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 Vaccine — United States, December 2020. Morbidity and Mortality Weekly Report 2020:20 de diciembre. [Ref.ID 103827]

4.

Anónimo. The COVID-19 Treatment Guidelines Panel’s statement on the Emergency use authorization of baricitinib for the treatment of COVID-19. National Institutes of Health 2020:14 de diciembre. [Ref.ID 103825]

5.

Parsons L. Moderna scores FDA panel backing for mRNA-based COVID-19 vaccine. PMLiVE 2020:18 de diciembre. [Ref.ID 103823]

6.

Parsons L. J&J completes enrolment for late-stage COVID-19 vaccine trial. PMLiVE 2020:1. [Ref.ID 103822]

7.

Grady D, Goodnough A, Zimmer C, Wu KJ. F.D.A. panel endorses Moderna’s Covid-19 vaccine. N Y Times (Print) 2020:1. [Ref.ID 103821]

8.

Weiland N, LaFraniere S, Baker M, Thomas K. 2 Alaska health workers got emergency treatment after receiving Pfizer’s vaccine. N Y Times (Print) 2020:16 de diciembre. [Ref.ID 103820]

9.

Herper M. FDA scientists endorse Moderna Covid-19 vaccine, as documents provide new hints on efficacy. STAT 2020:1. [Ref.ID 103819]

10.

Gil A. Europa acelera con las vacunas del coronavirus: preguntas y respuestas sobre el proceso de autorización. eldiario.es 2020:15 de diciembre. [Ref.ID 103818]

11.

Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical outcomes of a COVID-19 vaccine: implementation over efficacy. Health Affairs 2020:19 de noviembre. [Ref.ID 103809]

12.

Godlee F. Covid-19: The lost lessons of Tamiflu. BMJ 2020;371:3 de diciembre. [Ref.ID 103804]

13.

Hababi S, Heinrich A, Omer SB. No-fault compensation for vaccine injury — The other side of equitable access to covid-19 vaccines. N Engl J Med 2020;383:3 de diciembre. [Ref.ID 103803]

14.

Bloom BR, Nowak GJ, Orenstein W. “When will we have a vaccine?” — Understanding questions and answers about covid-19 vaccination. N Engl J Med 2020;383:3 de diciembre. [Ref.ID 103802]

15.

Efe. La ONU reconoce oficialmente las propiedades medicinales del cannabis. El Periódico 2020:2 de diciembre. [Ref.ID 103799]

16.

Grady D. Moderna applies for emergency F.D.A. approval for Its coronavirus vaccine. N Y Times (Print) 2020:30 de noviembre. [Ref.ID 103798]

17.

Doshi P. Pfizer and Moderna’s “95% effective” vaccines—let’s be cautious and first see the full data. BMJ 2020:26 de noviembre. [Ref.ID 103797]

18.

Anónimo. FDA sets 10 December date for Pfizer’s COVID-19 vaccine meeting. U.S. Food and Drug Administration 2020:20 de noviembre. [Ref.ID 103788]

19.

Anónimo. Coronavirus (COVID-19) Update: FDA authorizes monoclonal antibodies for treatment of COVID-19. U.S. Food and Drug Administration 2020:21 de noviembre. [Ref.ID 103785]

20.

Pathak EB. Convalescent plasma is ineffective for covid-19. BMJ 2020;371:22 de octubre. [Ref.ID 103776]